Jiezhong Chen1, Kristin Kaley2, Marie Carmel Garcon3, Teresa Rodriguez3, Muhammad Wasif Saif4. 1. School of Biomedical Sciences and Australian Institute of Bioengineering and Nanotechnology, University of Queensland, QLD, Australia. 2. School of Medicine, New Haven, CT, USA. 3. Columbia University Medical Center, New York, NY, USA. 4. Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine and Tufts Cancer Center, 800 Washington Street, Boston, MA 02111, USA.
Abstract
BACKGROUND: The objective of this study was to report a case series on the efficacy and safety of capecitabine 7/7 schedule combined with erlotinib (CAP-ERL) in patients with advanced pancreatic cancer (APC) who have failed prior therapies. METHODS: We retrospectively evaluated 13 patients with locally advanced or metastatic pancreatic cancer previously treated with gemcitabine or oxaliplatin-irinotecan-based first-line regimens. Treatment consisted of capecitabine (Xeloda) at a flat dose of 1000 mg orally twice daily on days 1-7 out of 14 days (7/7 schedule) and erlotinib (Tarceva) 100 mg orally once daily until unacceptable toxicity or disease progression. Tumor assessments were repeated every two cycles (8 weeks) and serum tumor markers were measured every 4 weeks. RESULTS: All patients (median age: 63 years; 7 female/3 male) had various previous lines of treatments of chemotherapies. Median number of cycles with CAP-ERL was 4 (range 2-12). The overall response rate was 20%. CA19-9 was reduced more than 25% in 40% patients. The median overall survival and progression-free survival from the start of CAP-ERL were 4.5 months (range 3-7.5) and 2 months (range 1.5-4), respectively. The most common grade 3 toxicities included hand-foot syndrome, nausea, vomiting, diarrhea, rash, and fatigue. CONCLUSIONS: Our result suggests that the combination of a fixed low dose of CAP-ERL 7/7 schedule was tolerated with manageable toxicity and showed encouraging activity as salvage treatment in patients with refractory APC with ECOG performance status 0-2. Further prospective studies are warranted to evaluate this combination.
BACKGROUND: The objective of this study was to report a case series on the efficacy and safety of capecitabine 7/7 schedule combined with erlotinib (CAP-ERL) in patients with advanced pancreatic cancer (APC) who have failed prior therapies. METHODS: We retrospectively evaluated 13 patients with locally advanced or metastatic pancreatic cancer previously treated with gemcitabine or oxaliplatin-irinotecan-based first-line regimens. Treatment consisted of capecitabine (Xeloda) at a flat dose of 1000 mg orally twice daily on days 1-7 out of 14 days (7/7 schedule) and erlotinib (Tarceva) 100 mg orally once daily until unacceptable toxicity or disease progression. Tumor assessments were repeated every two cycles (8 weeks) and serum tumor markers were measured every 4 weeks. RESULTS: All patients (median age: 63 years; 7 female/3 male) had various previous lines of treatments of chemotherapies. Median number of cycles with CAP-ERL was 4 (range 2-12). The overall response rate was 20%. CA19-9 was reduced more than 25% in 40% patients. The median overall survival and progression-free survival from the start of CAP-ERL were 4.5 months (range 3-7.5) and 2 months (range 1.5-4), respectively. The most common grade 3 toxicities included hand-foot syndrome, nausea, vomiting, diarrhea, rash, and fatigue. CONCLUSIONS: Our result suggests that the combination of a fixed low dose of CAP-ERL 7/7 schedule was tolerated with manageable toxicity and showed encouraging activity as salvage treatment in patients with refractory APC with ECOG performance status 0-2. Further prospective studies are warranted to evaluate this combination.
Authors: Stephan Kruger; Stefan Boeck; Volker Heinemann; Ruediger P Laubender; Ursula Vehling-Kaiser; Dirk Waldschmidt; Erika Kettner; Angela Märten; Cornelia Winkelmann; Stefan Klein; Georgi Kojouharoff; Thomas C Gauler; Ludwig Fischer von Weikersthal; Michael R Clemens; Michael Geissler; Tim F Greten; Susanna Hegewisch-Becker; Dominik P Modest; Sebastian Stintzing; Michael Haas Journal: Acta Oncol Date: 2015-04-30 Impact factor: 4.089
Authors: Wen Wee Ma; Joseph M Herman; Antonio Jimeno; Daniel Laheru; Wells A Messersmith; Christopher L Wolfgang; John L Cameron; Timothy M Pawlik; Ross C Donehower; Michelle A Rudek; Manuel Hidalgo Journal: Transl Oncol Date: 2010-12-01 Impact factor: 4.243
Authors: Stefan Boeck; Ralf Wilkowski; Christiane J Bruns; Rolf D Issels; Christoph Schulz; Nicolas Moosmann; Dorit Laessig; Michael Haas; Alexander Golf; Volker Heinemann Journal: Oncology Date: 2008-04-17 Impact factor: 2.935
Authors: Matthew H Kulke; Lawrence S Blaszkowsky; David P Ryan; Jeffrey W Clark; Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; Eunice L Kwak; Alona Muzikansky; Colleen Lawrence; Charles S Fuchs Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Rafael López; Carlos Méndez Méndez; Mónica Jorge Fernández; Carlos Romero Reinoso; Guillermo Quintero Aldana; Mercedes Salgado Fernández; Juan DE LA Cámara Gómez; Margarita Reboredo López; Manuel Ramos Vázquez; Sonia Candamio Folgar Journal: Anticancer Res Date: 2013-02 Impact factor: 2.480